Surf Bio is pioneering advancements in the delivery of biologics through its innovative Surf SnapShot™ technology. This platform allows for the administration of monoclonal antibodies (mAbs) at ultra-high concentrations exceeding 600 mg/mL, enabling patients to receive doses over 1,000 mg via a standard autoinjector in mere seconds, as opposed to the traditional hours-long intravenous infusions. The technology leverages a proprietary polymer that facilitates these high-concentration formulations, making subcutaneous delivery more accessible and patient-friendly. This approach not only enhances the convenience of at-home self-administration but also extends the intervals between doses, thereby improving the overall treatment experience for patients.

In addition to its core technology, Surf Bio is supported by a team of experienced professionals from diverse backgrounds in life sciences and engineering. The leadership includes co-founders Bryan Mazlish and Jennifer Schneider, MD, who bring extensive expertise in drug delivery systems and translational medicine. The company also collaborates with leading pharmaceutical firms to explore the potential of its SnapShot™ technology in various product pipelines, demonstrating its commitment to advancing healthcare solutions. Through ongoing research and partnerships, Surf Bio aims to redefine the landscape of biologic therapies, making them more efficient and accessible for patients worldwide.

United States

Surf Bio is a preclinical biopharmaceutical company that is transforming how antibodies and biologics are delivered to patients. Surf SnapShot™ technology enables mAb concentrations of 600+ mg/mL and delivery of a dose over 1,000 mg in a single, standard autoinjector shot. SnapShot’s™ ultra-high concentration formulations are uniquely powered by Surf Bio’s proprietary polymer, enabling the most accessible and patient-friendly subcutaneous delivery of mAbs and biologics. For more information about Surf Bio, visit www.surf.bio

Surf Bio

Company Details